Antibiotic resistance is a persistent and growing problem. Recurrent infections and antibiotic resistance is a major public health problem which accounts for over 80% of all infections annually in the US; greater than 1.7 million hospitalizations; approximately 75,000 deaths and $25B in US healthcare costs. Current antibiotics have limited effectiveness against biofilm-protected bacteria.
ProclaRx is developing an anti-infective technology that disrupts bacterial biofilms. Our protein-binding antibody technology removes the protein “bolts” which hold biofilms together. Disruption of the biofilm allows the host immune system and antibiotics to effectively attack the bacterial infection. The ProclaRx technology efficacy is demonstrated in animal models and in vitro. Persistent wounds, sinusitis, and otorrhea (ear infections) represent our leading indications.
Based on our animal studies, children with chronic ear infections who require T-Tube drains (700K/yr) will have an effective alternative. Accordingly, we anticipate reduced T-Tube durations and reduced antibiotic use while improving results. Pharmaceutical companies have shown interest in combining with our technology to breathe new life into antibiotics which show reduced effectiveness or which are coming off patent.
Bacteria produce a biofilm over time, shown from left to right. The biofilm appears as a cloudy covering with the bacteria inside.
The ProclaRx platform includes an antibody that binds to the proteins in the bacterial biofilm. Much like removing a rivet, the ProclaRx biologic pulls the proteins out of the biofilm matrix, causing the matrix to fall apart. The exposed bacteria can then be eradicated.
Bacterial biofilms, with protein in red
ProclaRx antibody that binds biofilm proteins
Bacterial biofilms to promote resistance to antibiotics. In response, the innovative researchers at ProclaRx are developing multiple anti-infective biologics. One is an antibody that disrupts the biofilm and thus increases antibiotic penetration. This antibody may be used as a topical adjunct in treatment of secretory otitis media, as well as in patients with Common Variable Immunodeficiency (CVID, an orphan indication) with chronic sinusitis. In addition, the company is developing an advanced wound care combination device aimed at improving healing by disrupting bacterial biofilms in the wound.
Clinical biofilm, Secretory Otitis Media
Clinical biofilm, Chronic Sinusitis
Clinical biofilm, wound care